Device Trial Radar · NCT01978470
External Trigeminal Nerve Stimulation for Drug Resistent Epilepsy
Last checked: Nov 20, 2026Latest source record: Apr 13, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
20
Planned (sponsor's estimate)
Start
Jun 2012
Primary completion
Jun 2016
Study completion Aug 2016
Sponsor
- Lead sponsor
- NeuroSigma, Inc.Not on our public-company list
- Sponsor type
- Industry
- Collaborators
- Olive View-UCLA Education & Research Institute
- First posted
- Nov 7, 2013
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the tolerability and safety of the NeuroSigma eTNS system.
Conditions
- Seizure Disorder
Interventions
External Trigeminal Nerve Stimulation (eTNS)Device
External stimulation of the trigeminal nerve.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety of eTNSTime frame: Four weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Olive View/UCLA Medical Center
Sylmar, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.